Alpha fetoprotein (AFP) response and efficacy outcomes in the phase 3 celestial trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)

Authors
Category Primary study
JournalOncology Research and Treatment
Year 2020
This article has no abstract
Epistemonikos ID: f38741028806983282ed2284238822986cd3d57d
First added on: Nov 24, 2025